Related Experiment Video
Updated: Jan 7, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Cardiogenic shock after ocrelizumab infusion in relapsing-remitting multiple sclerosis
Giulia De Napoli1, Enrico Gotti2, Chiara Baldovini3
1Department of Biomedical, Metabolic and Neurosciences, University of Modena and Reggio Emilia, Modena, Italy.
A patient with multiple sclerosis experienced severe cardiac dysfunction after ocrelizumab treatment. This rare side effect was reversible, emphasizing the need for cardiac monitoring during ocrelizumab therapy.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Ocrelizumab is a targeted therapy for MS, but its potential cardiac effects are not well-documented.
- Cardiac complications following ocrelizumab administration are rare but warrant investigation.
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiopulmonary Resuscitation IV: Pharmacological Management
Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Myocarditis IV: Nursing Management
Myocarditis III: Medical Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy

